Sign up Australia
Proactive Investors - Run By Investors For Investors

AusCann Group commences trading in the US increasing global exposure

The company aims to release its first medicinal cannabis products in FY2019.
men on the phone in an office
The cannabis sector in the US is gaining investor's attention

AusCann Group Holdings Ltd (ASX:AC8) (OTCQX:ACNNF) has commenced trading on the US OTCQX Market under the stock symbol ACNNF.

Trading on the OTCQX supports AusCann’s strategy to broaden its international investor base, particularly in North America where it has a number of strategic agreements in place.

The benefits of cross-trading in the US and expanded access to investors, diversification of the shareholder base, and enhancing the accessibility and liquidity of the company’s stock.

READ: Auscann Group makes steady progress towards production of cannabinoid medicines

AusCann’s managing director Elaine Darby said: “We believe the company will benefit significantly from the increased global exposure cross-trading will provide us and we look forward to strengthening our international partnerships.

“As regulatory changes are enacted worldwide and the benefits of cannabinoid medicines become more accepted, AusCann is seeing an increasing number of opportunities to expand its global footprint.”

AusCann aims to produce high quality, economical, and clinically validated cannabinoid medicines.

It has a vertically integrated strategy beginning with cultivation and production, through to manufacture and distribution of products.

This is made possible through a number of partnerships with industry leaders such as Canopy Growth Corp and Fundacion Daya.

The company is initially targeting medications for neuropathic and chronic pain in Australia and internationally, a market estimated to be worth $9 billion in Australia alone.

View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

picture of cannabis plants
March 24 2018
Control of the supply chain offers operational advantages and financial benefits.
woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use